Surrozen Inc (SRZN)

Currency in USD
31.910
+0.300(+0.95%)
Real-time Data·
SRZN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.77531.960
52 wk Range
12.52037.830
Key Statistics
Prev. Close
31.61
Open
31.34
Day's Range
30.775-31.96
52 wk Range
12.52-37.83
Volume
39.55K
Average Volume (3m)
527.25K
1-Year Change
145.8398%
Book Value / Share
-28.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SRZN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
63.500
Upside
+99.00%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Surrozen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 63.500
(+99.00% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy80.00+150.71%42.00Maintain11-11-2026
H.C. Wainwright
Buy54.00+69.23%44.00Maintain25-09-2026
William Blair
Buy---New Coverage20-08-2026
H.C. Wainwright
Buy44.00+37.89%-Maintain10-08-2026
H.C. Wainwright
Buy44.00+37.89%36.00Maintain07-05-2026

Earnings

Latest Release
09-11-2026
EPS / Forecast
-11.02 / -1.06
Revenue / Forecast
-- / 467.25K
EPS Revisions
Last 90 days

SRZN Income Statement

Compare SRZN to Peers and Sector

Metrics to compare
SRZN
Peers
Sector
Relationship
P/E Ratio
−1.5x−4.0x−0.2x
PEG Ratio
0.010.550.00
Price/Book
−1.8x2.3x2.6x
Price / LTM Sales
56.7x7.0x2.8x
Upside (Analyst Target)
100.5%160.5%65.0%
Fair Value Upside
Unlock0.9%9.5%Unlock

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.21M6.35%38.25M
Other Institutional Investors
21.07M93.65%666.18M
Public Companies & Retail Investors
0.000.00%0.00
Total
22.28M100.00%704.43M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Column Group, LLC20.01%38,13,5011,20,545
Column Group III, LP7.27%13,86,12243,815

FAQ

What Is the Surrozen (SRZN) Share Price Today?

The Surrozen share price today is 31.910.

What is the current Surrozen (SRZN) share price and day range?

As of 16-11-2026, the Surrozen share price is 31.910, with a previous close of 31.610. The share price has ranged from 30.775 to 31.960 today, while the 52-week range spans from 12.520 to 37.830.

What Is the Surrozen Market Cap?

As of today, Surrozen market cap is 602.540M.

What Is the Surrozen (SRZN) Share Price Target?

The average 12-month share price target for Surrozen is 63.500, with a high estimate of 80 and a low estimate of 54. 6 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +99.00% Upside potential.

What Is Surrozen's Earnings Per Share (TTM)?

The Surrozen EPS (TTM) is -35.87.

When Is the Next Surrozen Earnings Date?

Surrozen will release its next earnings report on 25-03-2027.

From a Technical Analysis Perspective, Is SRZN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Surrozen Trade On?

Surrozen is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Surrozen?

The stock symbol for Surrozen is "SRZN."

How Many Times Has Surrozen Stock Split?

Surrozen has split 1 times.

How Many Employees Does Surrozen Have?

Surrozen has 44 employees.

What Is the SRZN Premarket Price?

SRZN's last pre-market stock price is 31.620. The pre-market share volume is 50.000, and the stock has changed by 0.010, or 0.030%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.